A. Verbon et al., IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans, J IMMUNOL, 166(5), 2001, pp. 3599-3605
CD14 is a receptor for cell wall components of Gram-negative and Gram-posit
ive bacteria that has been implicated in the initiation of the inflammatory
response to sepsis, To determine the role of CD14 in LPS-induced effects i
n humans, 16 healthy subjects received an i.v. injection of LPS (4 ng/kg) p
receded (-2 h) by i.v. IC14, a recombinant chimeric mAb against human CD14,
at a dose of 1 mg/kg over 1 h, or placebo. In subjects receiving IC14, sat
uration of CD14 on circulating monocytes and granulocytes was >90% at the t
ime of LPS injection. IC14 attenuated LPS-induced clinical symptoms and str
ongly inhibited LPS-induced proinflammatory cytokine release, while only de
laying the release of the anti-inflammatory cytokines soluble TNF receptor
type I and IL-1 receptor antagonist. IC14 also inhibited leukocyte activati
on, but more modestly reduced endothelial cell activation and the acute pha
se protein response. The capacity of circulating monocytes and granulocytes
to phagocytose Escherichia coli was only marginally reduced after infusion
of IC14. These data provide the first proof of principle that blockade of
CD14 is associated with reduced LPS responsiveness in humans in vivo.